You recently wrote about a study regarding aspirin therapy for people with high Lp(a) levels. What is the current thinking?

Ph.D., Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. "The first joint therapeutic project entered the clinic last ...

“I am delighted to see Broad and Bayer continue this fruitful collaboration in cardiovascular research,” said Todd Golub, director and founding core member of the Broad Institute. “By ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

Bayer and the Broad Institute announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

A major international study has found that heart patients, particularly seniors, may benefit more from newer blood-thinning ...